公开(公告)号：US10449144B2

公开(公告)日：2019-10-22

申请号：US14166932

申请日：2014-01-29

Applicant: NITTO DENKO CORPORATION ,  OSAKA UNIVERSITY

Inventor： Katsuyuki Okubo ,  Yoshiki Maeda ,  Arimichi Okazaki ,  Daisuke Asari ,  Takuya Shishido ,  Mitsuhiko Hori ,  Haruo Sugiyama

IPC: A61K9/00 ,  A61K38/10 ,  A61K39/00

Abstract: The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.

公开(公告)号：US10420837B2

公开(公告)日：2019-09-24

申请号：US15514868

申请日：2015-10-01

Applicant: NITTO DENKO CORPORATION

Inventor： Takuya Shishido ,  Daisuke Asari ,  Kyohei Matsushita ,  Katsuyuki Okubo ,  Mitsuhiko Hori

IPC: A61K39/39 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K9/70

Abstract: The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt, derived from at least one gram-negative bacterium such as Serratia, Lelercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant/the total mass of the antigen, of 0.002 to 500.

公开(公告)号：US10071051B2

公开(公告)日：2018-09-11

申请号：US14166950

申请日：2014-01-29

Applicant: NITTO DENKO CORPORATION ,  OSAKA UNIVERSITY

Inventor： Katsuyuki Okubo ,  Yoshiki Maeda ,  Arimichi Okazaki ,  Daisuke Asari ,  Takuya Shishido ,  Mitsuhiko Hori ,  Haruo Sugiyama

IPC: A61K9/00 ,  A61K38/10 ,  A61K39/00 ,  A61K31/045 ,  A61K31/437 ,  A61K31/451 ,  A61K31/513 ,  A61K31/708 ,  A61K31/716 ,  A61K31/728 ,  A61K31/739

CPC classification number: A61K9/0014 ,  A61K31/045 ,  A61K31/437 ,  A61K31/451 ,  A61K31/513 ,  A61K31/708 ,  A61K31/716 ,  A61K31/728 ,  A61K31/739 ,  A61K38/10 ,  A61K39/0011 ,  A61K2039/54

Abstract: The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.